JINLING PHARM.(SZ:000919)2016-08-22 16:00Financial Performance - The company's operating revenue for the first half of 2016 was ¥1,808,452,125.78, representing a 15.34% increase compared to ¥1,567,871,876.59 in the same period last year[20]. - The net profit attributable to shareholders of the listed company decreased by 5.32% to ¥109,754,704.45 from ¥115,917,146.85 in the previous year[20]. - The net profit after deducting non-recurring gains and losses increased by 5.31% to ¥105,049,593.87 compared to ¥99,755,966.02 in the same period last year[20]. - The basic earnings per share decreased by 5.30% to ¥0.2178 from ¥0.2300 in the same period last year[20]. - The diluted earnings per share also decreased by 5.30% to ¥0.2178 from ¥0.2300 in the previous year[20]. - The weighted average return on equity was 4.39%, down from 4.87% in the same period last year[20]. - The company achieved total operating revenue of CNY 1,808,452,125.78, representing a year-on-year increase of 15.34%[34]. - Operating profit for the period was CNY 16,513.05 million, with a net profit attributable to the parent company of CNY 10,975.47 million[28]. - Jinling Pharmaceutical reported a revenue of 600 million in the first half of 2016, representing a 14.24% increase compared to the same period in 2015[46]. - The company achieved a net profit of 83.48 million in the first half of 2016, reflecting a growth of 60.83% year-over-year[46]. - The company reported a total of 504 million shares outstanding, with 99.84% being unrestricted shares[92]. - The company reported a total of 1,067,6450.285 in retained earnings at the end of the period[142]. Cash Flow and Assets - The net cash flow from operating activities was negative at -¥60,089,120.18, a decline of 171.38% from ¥84,183,697.74 in the previous year[20]. - The total assets at the end of the reporting period were ¥4,041,715,524.77, an increase of 4.97% from ¥3,850,257,581.02 at the end of the previous year[20]. - The net cash flow from operating activities was ¥4,464,614.12, a decrease of 88% compared to ¥37,239,889.64 in the previous period[131]. - Cash inflow from operating activities totaled ¥324,651,784.19, down 12% from ¥367,932,469.33 year-over-year[131]. - Cash outflow from operating activities was ¥320,187,170.07, a decrease of 3% compared to ¥330,692,579.69 in the previous period[131]. - The company reported a total current assets of RMB 2,613,847,347.90, up from RMB 2,414,596,849.86, reflecting an increase of about 8.25%[110]. - The total non-current assets decreased slightly to RMB 1,427,868,176.87 from RMB 1,435,660,731.16, showing a decline of approximately 0.55%[110]. - The company's cash and cash equivalents increased to RMB 770,375,477.37 from RMB 698,177,060.62, representing a rise of about 10.2%[110]. - Accounts receivable rose significantly to RMB 654,430,440.52 from RMB 479,817,001.73, indicating an increase of approximately 36.4%[110]. - Inventory levels increased to RMB 467,465,153.64 from RMB 413,932,181.05, marking a growth of around 12.9%[110]. - Short-term borrowings increased to RMB 125,000,000.00 from RMB 84,000,000.00, which is an increase of approximately 48.8%[110]. Investments and R&D - The company's R&D investment increased by 10.94% to CNY 16,492,698.79[34]. - The company is investing 100 million in R&D for new product development, focusing on innovative drug formulations and delivery systems[46]. - The company has invested CNY 17,285,030 in Huatai Zijin Fund, holding 17.77% of shares at the end of the period, with a report period gain of CNY 22,982[41]. - The company has a total of CNY 600,000 in entrusted financial management with a reported income of CNY 3.15 from Nanjing Bank[45]. - The company has introduced a new line of herbal medicines, which is expected to contribute an additional 50 million in revenue by the end of 2016[46]. Market Strategy and Expansion - Jinling Pharmaceutical plans to expand its market presence by entering three new provinces by the end of 2016, aiming for a 10% market share in these regions[46]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach, with a budget allocation of 200 million for this purpose[46]. - The company successfully launched a new DTC/DTP pharmacy in Yizheng, expanding its retail presence[29]. - The company completed nearly 30 cardiac interventional surgeries at the newly established DSA diagnostic center in Yizheng Hospital[30]. Governance and Compliance - The governance structure of the company has been improved in compliance with relevant laws and regulations[62]. - The company did not engage in any derivative investments or entrusted loans during the reporting period[49][50]. - There were no major litigation or arbitration matters reported during the period[63]. - The company did not conduct any significant non-fundraising investment projects during the reporting period[55]. - The company has no significant contracts or their performance issues during the reporting period[81]. - The company did not experience any media controversies during the reporting period[64]. Financial Reporting and Standards - The half-year financial report has not been audited[85]. - The financial statements comply with the requirements of the accounting standards, accurately reflecting the company's financial position, operating results, and cash flows[155]. - The company prepares financial statements based on the going concern assumption, following the accounting standards issued by the Ministry of Finance[153]. - The company recognizes revenue based on specific accounting policies tailored to its operational characteristics[154]. Shareholder Information - The profit distribution plan for 2015 was approved, with a cash dividend of 1.70 yuan per 10 shares, totaling approximately 85.68 million yuan distributed to shareholders[56]. - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[6]. - The largest shareholder, Nanjing New工 Investment Group, holds 45.23% of the shares, totaling approximately 227.94 million shares[95]. - The company has 28,994 common stock shareholders as of the end of the reporting period[95].